Literature DB >> 30171049

PD Solutions and Peritoneal Health.

Yeoungjee Cho1,2, David W Johnson3,2,4.   

Abstract

Entities:  

Keywords:  Chronic inflammation; Dialysis Solutions; Epidemiology and outcomes; Peritoneum; peritoneal dialysis; peritoneal membrane; ultrafiltration

Mesh：

Substances：

Year:  2018        PMID： 30171049      PMCID： PMC6218828          DOI： 10.2215/CJN.09590818

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  10 in total

1.  Morphologic changes in the peritoneal membrane of patients with renal disease.

Authors:  John D Williams; Kathrine J Craig; Nicholas Topley; Christopher Von Ruhland; Maureen Fallon; Geoffrey R Newman; Ruth K Mackenzie; Geraint T Williams
Journal:  J Am Soc Nephrol       Date:  2002-02       Impact factor: 10.121

Review 2.  Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions.

Authors:  Olivier Devuyst; Nicholas Topley; John D Williams
Journal:  Nephrol Dial Transplant       Date:  2002       Impact factor: 5.992

3.  Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis.

Authors:  K Scott Brimble; Michelle Walker; Peter J Margetts; Kiran K Kundhal; Christian G Rabbat
Journal:  J Am Soc Nephrol       Date:  2006-08-02       Impact factor: 10.121

4.  Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose-enriched, lactated, buffered dialysis solutions.

Authors:  L Gotloib; V Waisbrut; A Shostak; R Kushnier
Journal:  Nephron       Date:  1995       Impact factor: 2.847

5.  Peritoneal morphology after long-term peritoneal dialysis with biocompatible fluid: recent clinical practice in Japan.

Authors:  Nobuhiro Ayuzawa; Yoshitaka Ishibashi; Yutaka Takazawa; Haruki Kume; Toshiro Fujita
Journal:  Perit Dial Int       Date:  2011-07-31       Impact factor: 1.756

6.  The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

7.  Biocompatible Solutions and Long-Term Changes in Peritoneal Solute Transport.

Authors:  Emma H Elphick; Lucy Teece; James A Chess; Jun-Young Do; Yong-Lim Kim; H Bahl Lee; Sara N Davison; Nicholas Topley; Simon J Davies; Mark Lambie
Journal:  Clin J Am Soc Nephrol       Date:  2018-08-31       Impact factor: 8.237

8.  Glucose dialysate induces mitochondrial DNA damage in peritoneal mesothelial cells.

Authors:  Yoshitaka Ishibashi; Tokuichiro Sugimoto; Yasuko Ichikawa; Akira Akatsuka; Toshio Miyata; Masaomi Nangaku; Hitoshi Tagawa; Kiyoshi Kurokawa
Journal:  Perit Dial Int       Date:  2002 Jan-Feb       Impact factor: 1.756

9.  The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.

Authors:  David W Johnson; Fiona G Brown; Margaret Clarke; Neil Boudville; Tony J Elias; Marjorie W Y Foo; Bernard Jones; Hemant Kulkarni; Robyn Langham; Dwarakanathan Ranganathan; John Schollum; Michael G Suranyi; Seng H Tan; David Voss
Journal:  Nephrol Dial Transplant       Date:  2012-08-01       Impact factor: 5.992

10.  Biocompatible dialysis fluids for peritoneal dialysis.

Authors:  Htay Htay; David W Johnson; Kathryn J Wiggins; Sunil V Badve; Jonathan C Craig; Giovanni Fm Strippoli; Yeoungjee Cho
Journal:  Cochrane Database Syst Rev       Date:  2018-10-26
  10 in total
  1 in total

1.  Expression of XBP1s in peritoneal mesothelial cells is critical for inflammation-induced peritoneal fibrosis.

Authors:  An Liu; Qiong Song; Yong Zheng; Guoshuang Xu; Chen Huang; Shiren Sun; Lijie He; Lijuan Zhao; Meilan Zhou
Journal:  Sci Rep       Date:  2019-12-13       Impact factor: 4.379
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.